🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Register now to join us live on Thursday 13th January 2022 ibd-edinburgh.co.uk

@drlauriekeefer introducing her talk next week Lauri is a health psychologist working to help improve resilience in IBD patients She is leading this field with actionable protocols rooted in careful research She is co-founder of Trellus Health Details to register 👇

This ⁦⁦National Institute for Health and Care Research⁩ Prod. featuring ⁦Tariq Ahmad⁩ ⁦CLARITY IBD⁩ is worth a listen. Great tips on how to conduct a large study at pace. ⁦⁦IBDHull⁩ privileged to play a very small part.Great interview ⁦Tariq Iqbal⁩ open.spotify.com/episode/2QvdnV…

Well done to Y-ECCO best abstract award winners 👏👏 + A special shout out to Simeng Lin and workshop contributor @nchanchlani1 ExeterIBDresearch

Case study: CLARITY IBD: Changing the way we do research | NIHR nihr.ac.uk/documents/case…

Dr Tariq Ahmad Tariq Ahmad discussing CLARITY IBD. How enabling research during the covid era, could change the way we do research in the future. #patientledresearch #electronicconsent #collaboration

Wow, thank you @EmmaHHFT and Team @HHFTResearch Hampshire Hospitals. Your contribution and hard work to CLARITY IBD has been invaluable.

Tariq Ahmad Nick Kennedy James Goodhand NickPowellLab Charlie Lees Seb Aamir Saifuddin @nchanchlani1 Claire Bewshea We are pleased to share our latest manuscript from the CLARITY IBD study is now published in Nature Communications Thank you to all our CLARITY IBD contributors, patients, and collaborators. nature.com/articles/s4146…

Brilliant study led by @philip_j_smith just out in #JCC exploring switching from IV to s/c IFX. Well done team. academic.oup.com/ecco-jcc/advan…

Withdrawal of BSG IBD risk grid for COVID severity Gut Journal • reassuring for patients, with • vaccines, boosters and antivirals "We predict that the disruption from the pandemic for individuals with IBD will largely be no different to the general population."

Results from the latest CLARITY IBD paper published in Gut Journal summarised here:

👀If you haven’t seen it yet - the latest results from CLARITY IBD are summarised 👇 Thank you 🙏 to all 7000 patients and 92 research sites - this wouldn’t happen without YOU 👍 #Collaboration #ibdpatients #ibdresearch #COVID19 Gut Journal

Drug commonly used to treat inflammatory bowel disease limits protection given by 3rd #COVID #vaccine dose, finds new study from CLARITY IBD People on Infliximab were more than twice as likely to get a breakthrough infection. Read the full story 👇 covidvaccineresearch.org/news/drug-comm…

👀More data from VIP Study Main message for #IBDpatients - ✔️ get NEW boosters = protection against Omicron variants. New boosters especially ☑️☑️ for those on anti -TNF and tofacitinib drugs. #COVID19Ab #IBD Gastroenterology NickPowellLab

👀More data from VIP Study Main message for #IBDpatients - ✔️ get NEW boosters = protection against Omicron variants. New boosters especially ☑️☑️ for those on anti -TNF and tofacitinib drugs. #COVID19Ab #IBD Gastroenterology NickPowellLab gastrojournal.org/article/S0016-…

New CLARITY IBD findings 👇 ❗to continue SARS-CoV-2 vaccination programmes, inc. second-generation bivalent vaccines. Esp when vaccine immunogenicity and efficacy might be reduced, such as those on anti-TNF therapies. Great work, thank you 👏👏👏 #ibdpatients Be Part of Research

We are glad to share that our latest manuscript from the CLARITY IBD study is now published in The Lancet Gastroenterology & Hepatology. Thank you to all CLARITY IBD contributors, patients, and collaborators!